Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia | NEJM
Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia | Critical Care | Full Text
Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia | Critical Care | Full Text
Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease - ScienceDirect
Diagram of the nebulization setup | Download Scientific Diagram
Oral Inhaled Medications—Beyond Bronchodilators
Frontiers | Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
Dosing | ARIKAYCE® (amikacin liposome inhalation suspension)
Dosing | ARIKAYCE® (amikacin liposome inhalation suspension)
The Unfulfilled Promise of Inhaled Therapy in Ventilator-Associated Infections: Where Do We Go from Here? | Journal of Aerosol Medicine and Pulmonary Drug Delivery
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial - The Lancet Infectious Diseases
Nebulizer Use for Dogs and Cats - Veterinary Partner - VIN
Is ARIKAYCE® Right for You? | ARIKAYCE® (amikacin liposome inhalation suspension)
Antibiotics | Free Full-Text | How to Use Nebulized Antibiotics in Severe Respiratory Infections
PDF) Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials
Frontiers | Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
ARIKAYCE (amikacin liposome inhalation suspension) Academy
Mean cumulative systemic absorption of amikacin as a function of time.... | Download Scientific Diagram
PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension)
Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia – topic of research paper in Medical engineering. Download scholarly article PDF and read for
Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease | Antimicrobial Agents and Chemotherapy
Aerosolized Antibiotics | Respiratory Care
Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects | Intensive Care Medicine
Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects | Intensive Care Medicine
